Matches in Wikidata for { <http://www.wikidata.org/entity/Q92804462> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q92804462 description "article scientifique publié en 2019" @default.
- Q92804462 description "artículu científicu espublizáu n'agostu de 2019" @default.
- Q92804462 description "im August 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92804462 description "scientific article published on 22 August 2019" @default.
- Q92804462 description "wetenschappelijk artikel" @default.
- Q92804462 description "наукова стаття, опублікована 22 серпня 2019" @default.
- Q92804462 name "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide" @default.
- Q92804462 name "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide" @default.
- Q92804462 type Item @default.
- Q92804462 label "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide" @default.
- Q92804462 label "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide" @default.
- Q92804462 prefLabel "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide" @default.
- Q92804462 prefLabel "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide" @default.
- Q92804462 P1433 Q92804462-D50AEBA6-EB4F-45FF-8CBF-DD54ABC53BE8 @default.
- Q92804462 P1476 Q92804462-C3950377-F8ED-4556-AF36-2D78B231F14F @default.
- Q92804462 P2093 Q92804462-1A91C9E7-6C8A-4F5C-B72D-8496F77890B1 @default.
- Q92804462 P2093 Q92804462-2DE6F1CA-C5FD-4528-B6C4-3F5CE9A39B11 @default.
- Q92804462 P2093 Q92804462-8E5254FE-05C1-4466-945D-9F5B5E8BFA0C @default.
- Q92804462 P2093 Q92804462-930BE15C-68ED-41CB-8F3A-6601E77E7A43 @default.
- Q92804462 P2093 Q92804462-A8BE47C3-EA7F-444F-A5AD-83D312D76921 @default.
- Q92804462 P2093 Q92804462-A8EC701B-BBD9-4FA2-8655-718538BD5446 @default.
- Q92804462 P2093 Q92804462-BB502F2B-97B6-4C25-9CD5-3F0ED7883150 @default.
- Q92804462 P2093 Q92804462-E72E275D-8D50-44BD-8425-786F364B0BD9 @default.
- Q92804462 P2093 Q92804462-F8FCA397-7499-4F65-AB19-40E88394172F @default.
- Q92804462 P304 Q92804462-9CA74453-E2B5-4BC5-B086-43D98F04BFB5 @default.
- Q92804462 P31 Q92804462-1E2E81D0-AC5D-400C-9F08-F6B069649AF5 @default.
- Q92804462 P356 Q92804462-8F61724E-66DB-4E39-9626-990D47CDDDE2 @default.
- Q92804462 P433 Q92804462-1D00417F-3BFA-4287-A9D2-59969805FEA7 @default.
- Q92804462 P478 Q92804462-3CD774EE-DBD9-4B87-B6FF-80424BC49C4E @default.
- Q92804462 P50 Q92804462-484F1963-9E2A-40F1-83B2-BC7E11F92743 @default.
- Q92804462 P50 Q92804462-D9DFAF43-B07F-4923-8BB5-2FC87C4CAC86 @default.
- Q92804462 P50 Q92804462-E4DB63BA-9E7B-44F4-B8CB-A7BEA5EAAA7F @default.
- Q92804462 P577 Q92804462-D29BD8CE-EF7B-4589-8FDC-4B0F4E7D84D0 @default.
- Q92804462 P698 Q92804462-61FDF66C-A0DC-4366-83C0-63FB65901448 @default.
- Q92804462 P921 Q92804462-048F0D16-2AFB-46E2-91A6-ACB9A5BD7688 @default.
- Q92804462 P921 Q92804462-20C05F58-FCB6-4E23-815C-2980375BCC08 @default.
- Q92804462 P356 S00520-019-05039-X @default.
- Q92804462 P698 31440823 @default.
- Q92804462 P1433 Q15766919 @default.
- Q92804462 P1476 "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide" @default.
- Q92804462 P2093 "Dina M Randazzo" @default.
- Q92804462 P2093 "Elizabeth Miller" @default.
- Q92804462 P2093 "Eric S Lipp" @default.
- Q92804462 P2093 "Henry S Friedman" @default.
- Q92804462 P2093 "James E Herndon" @default.
- Q92804462 P2093 "Katherine B Peters" @default.
- Q92804462 P2093 "Mallika P Patel" @default.
- Q92804462 P2093 "Patrick Healy" @default.
- Q92804462 P2093 "Sarah Woodring" @default.
- Q92804462 P304 "2229-2238" @default.
- Q92804462 P31 Q13442814 @default.
- Q92804462 P356 "10.1007/S00520-019-05039-X" @default.
- Q92804462 P433 "5" @default.
- Q92804462 P478 "28" @default.
- Q92804462 P50 Q104937686 @default.
- Q92804462 P50 Q73536038 @default.
- Q92804462 P50 Q92804455 @default.
- Q92804462 P577 "2019-08-22T00:00:00Z" @default.
- Q92804462 P698 "31440823" @default.
- Q92804462 P921 Q425088 @default.
- Q92804462 P921 Q42824440 @default.